Alnylam Pharmaceuticals
ALNYAlnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that pioneered the development of RNA interference (RNAi) therapeutics.
Earnings
Next report
Oct 29, 2026 (in 2 months)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that pioneered the development of RNA interference (RNAi) therapeutics. The company utilizes small interfering RNA (siRNA) to silence specific messenger RNA (mRNA) molecules, preventing the production of disease-causing proteins. Their platform focuses on genetic medicines for rare and prevalent diseases, leveraging proprietary delivery technologies like GalNAc conjugates and lipid nanoparticles.
Alnylam is the industry leader in RNAi therapeutics, holding the first-mover advantage with multiple approved products and a dominant intellectual property position in siRNA delivery.
FAQ
- What is Alnylam Pharmaceuticals's market cap?
- Alnylam Pharmaceuticals (ALNY) has a market capitalization of $32.0B and trades on NASDAQ.
- What is Alnylam Pharmaceuticals's revenue and profitability?
- Alnylam Pharmaceuticals generated $4.8B in trailing twelve-month revenue with net income of $733.1M, representing a net margin of 15.3%. Gross margin stands at 79.8%, with free cash flow of $793.9M. These figures are based on the Q2 2026 filing.
- Who are Alnylam Pharmaceuticals's competitors?
- Alnylam Pharmaceuticals's key competitors include Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Moderna, and others. These companies compete in similar markets and product categories.
- Who does Alnylam Pharmaceuticals partner with?
- Alnylam Pharmaceuticals's notable partners include Novartis, Sanofi, Regeneron Pharmaceuticals.
- Where is Alnylam Pharmaceuticals headquartered?
- Alnylam Pharmaceuticals is headquartered in United States of America and employs approximately 2,100 people. It has been publicly traded since 2004.
